The cancer diagnostics and profiling markets are growing, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. Technological breakthroughs are creating numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in the geriatric population is further compounding the growing demand for malignancy assays and the rapid market expansion. The driving factors for the growth of the cancer therapeutics market in Germany include: Ease in regulatory approval, Increased healthcare spending for cancer, Rising prevalence of cancer and Strong R&D initiatives from key players. The direct cost of cancer has also increased, and thus, the cost of cancer drugs as a share of direct health costs has doubled. The increase in the cost of cancer treatment, along with drug prices, has resulted in the growth of the overall market. In addition, the heavy investments made in R&D activities have enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and a surge in cancer prevalence have boosted the market growth. Visit https://insights10.com/ for more healthcare industry insights. Connect with us at info@insights10.com

1. Germany
Oncology Market
Analysis
Germany Oncology Market Analysis– Segmented by-
Cancer Type, Treatment Type, and End User 2020
forecasted till 2028
Sample Report

2. 2 Confidential
Table Of Content
1. German Oncology Market Overview……………………...………………………………………..…………………..……………………………..………………...…05
a. Market size and forecast
2. Market Growth Drivers & Restraints……………………………………………………………………………………………………………...……...........................07
a. Market Growth Drivers
i. Increase in the number of cases
ii. Effective immunotherapies
iii.Government initiatives
iv.Technological advancements
b. Market Restraints
i. High cost associated with the therapy
ii. Regulatory issues
3. Epidemiology…………………………………………………………………………………………………………………………………………………………………..14
a. Number of New Cases in 2020
b. Incidence and Mortality Rate
4. Germany Oncology Market Segmentation…………………………………………………………………………………………………………….………………….16
a. By Cancer Type
i. Breast Cancer
ii. Lung Cancer
iii.Colorectal Cancer

3. 3 Confidential
Table Of Content
iv.Ovarian Cancer
v. Blood Cancer
vi.Others
b. By Treatment Type
i. Chemotherapy
ii. Target Therapy
iii.Immunotherapy
iv.Hormonal Therapy
c. By End User
i. Hospitals
ii. Specialty Clinics
iii.Cancer and Radiation Therapy Centers
5. Competitive Landscape……………………………………………………………………………………………………………………………………………........…...21
a. Major companies for Germany Oncology Market
b. Key Player Market Share
6. Key Company Profiles……………………………………………………………………………………………………………………………………………..…….......24
i. Elekta AB Company Overview, Product, Services, Strategies and Financials

4. 4 Confidential
Table Of Content
ii. Cerner Corp. Company Overview, Product, Services, Strategies and Financials
iii. Varian Medical Systems, Inc. Company Overview, Product, Services, Strategies and Financials
iv. Qiagen N.V. Company Overview, Product, Services, Strategies and Financials
v. Becton Dickinson Company Overview, Product, Services, Strategies and Financials
vi. Koninklijke Philips N.V. Company Overview, Product, Services, Strategies and Financials
7. Healthcare Policy and Regulatory Landscape……………………………………………………………………………………………………………………………37
a. Policy changes and Regulatory Landscape
8. Access and Reimbursement Scenario…………………………………………………………………………………………………………………………………….39
a. Key Market Access Consideration
b. General Reimbursement Scenario
9. Factors Driving Future Growth………………………..………………………………………………………………………………..………...……...….....................41
a. Recent Developments in the Germany Oncology market
b. Future Opportunities
10.Conclusion…………………………………………………………………………………………………………………………………………………………..………….44

5. Global Patient Support Program: Market Overview

6. 6 Confidential
Germany Oncology Market Size (Current and Forecasted)
Germany Oncology Market Size (Mn)
2020-2028F
 Germany’s Oncological therapeutics market size stood at
around $xx Bn in 2020 and is projected to reach $xx Bn by
2028, exhibiting a CAGR of 7.3% during the forecast period
 Germany is one of the major economies in Europe which is
considerably influencing the European oncology information
system market
 Well-developed healthcare infrastructure coupled with the
increased penetration of digitalization and the significant
prevalence of cancer in the country is expected to surge the
oncology information system market size within the country
XX
XX
2020 2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F
Market Size
Key Analysis

7. Germany Oncology Market: Growth Drivers And
Growth Restraints

8. 8 Confidential
Market Growth Drivers And Restraints
Increase in the number of
new cases Technological advancements
Regulatory issues
High cost associated with the
therapies
Impact
Impact
Market
Drivers
Market
Restraints
Government initiatives
Effective
immunotherapies

9. 9 Confidential
Market Growth Drivers
Increasing geriatric population owing to which the risk associated with numerous types of cancers is expected to increase significantly in the
future years
Content
Content
1. Increase in the number of new cases

10. 10 Confidential
Market Growth Drivers (continued)
2. Effective immunotherapies
Immunotherapy is preferred over tradition treatment options because it provides long-term cancer protection, has less side effects, and treats a
wider range of cancer
Gene therapies are giving excellent results in clinical trials and are proving to be effective in case of cancer treatment which is a major boost
for the Oncology market
Content

11. 11 Confidential
Market Growth Drivers (continued)
3. Government initiatives
Germany has the highest expenditure on health as a share of its Gross Domestic Product (GDP) in the European Union (EU), and the
second highest in terms of health spending per capita
Favorable government regulations for cancer therapeutics and insurance policies have boosted the market growth
Content

12. 12 Confidential
Market Growth Drivers (continued)
4. Technological advancements
Technological breakthroughs are creating numerous opportunities for determining genetic predisposition, detecting specific tumors, and
monitoring biological response to cancer therapy
Content
Content

13. 13 Confidential
High cost associated with the therapies Regulatory issues
 New drugs and treatment options take time to undergo
clinical trials process
 New cancer drugs can be marketed at very high prices
due to a lack a strong regulatory framework in many
markets
 Direct cost of cancer has also increased, and thus, the
cost of cancer drugs as a share of direct health costs
has doubled
 Increase in the cost of cancer treatment, along with
drug prices, has increased the burden of expense on
the patients seeking cancer treatment
Market Restraints

14. Germany Oncology Market: Epidemiology

15. 15 Confidential
Epidemiology
 Total Population: 83.7M
 Number of new cases: 0.6M
 Number of death: 0.2M
 Number of prevalent cases (5-year): 2.1M
Numbers at a Glance in 2020 Cancer Incidence Mortality
Breast 69,697 20,579
Lung 64,804 50,282
Colorectal 54,958 26,395
Ovarian 7,168 5,326
Blood 13,796 9,428
All Cancer Sites 628,519 252,065

16. Germany Oncology: Market Segmentation

17. 17 Confidential
Oncology Market Segmentation
Germany Oncology Market Segmentation
By End-User
Cancer and Radiation
Therapy Centers
Hospitals
Specialty Cases
By Treatment Type
Immunotherapy
Hormonal Therapy
Chemotherapy
Target Therapy
Breast Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Ovarian Cancer
Blood Cancer
Others
By Cancer Type

18. 18 Confidential
 Breast Cancer cases were seen to be the highest gaining
11.1% of the total cases observed in Germany followed by
Lung Cancer and Colorectal cancer in the total cases
observed in 2020
 Breast Cancer is leading with its Incidence rates standing
at 82.2 whereas Lung cancer has the highest mortality
rate of 23.1
Market Segmentation: By Cancer Type
Germany Oncology Market Share by Cancer Type 2020
Breast Cancer Lung Cancer
Colorectal Cancer Ovarian Cancer
Blood Cancer Others
Key Insights

19. 19 Confidential
Market Segmentation: By Treatment Type
Chemotherapy Target therapy
Immunotherapy Hormonal Therapy
Key Insights
Germany Oncology Market Share by Treatment Type
2020
Sample

20. 20 Confidential
Market Segmentation: By End User
Germany Oncology Market Share by End User 2020
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Key Insights
Sample

21. Germany Oncology Market: Competitive
Landscape

22. 22 Confidential
Competitive Landscape: Key Players Revenue (Current and Forecasted)
2020 2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F
Elekta AB $1.6 - - - - - - - -
Cerner Corp. $5.5 - - - - - - - -
Varian Medical
Systems
$3.2 - - - - - - - -
Qiagen N.V. $0.001 - - - - - - - -
Becton Dickinson $4.8 - - - - - - - -
Koninklijke Philips
N.V.
$22.3 - - - - - - - -
Major Market Revenue of German Oncology market Companies ($Bn)

23. 23 Confidential
 German Oncology market is highly competitive with multiple
players coming up with innovative products or innovative
diagnosis measures
 With technological advancements in Germany there is a
great opportunity for companies to invest in the oncology
market
Elekta AB Cerner Corp.
Varian Medical Systems Qiagen N.V.
Becton Dickinson Koninklijke Philips N.V.
Mckesson Corp IBM Corp
Competitive Landscape: Key Players Market Share
Key Insights
Patient Support Program Key Players Major Market Share
Sample

24. Key Company Profiles

25. 25 Confidential
Elekta AB
Company Profile
Company Name: Elekta AB
Year of Establishment: 1972
Headquarter: Sweden
Revenue: $1.6 Bn
Website: https://www.elekta.com/
Sample

26. 26 Confidential
Elekta AB
Analysis
Breakdown of net revenue (%) by segment, 2020
Revenues ($Bn), 2020-2028
 Elekta has a strong position in emerging markets and continues to grow, offering more patients greater hope for better
outcomes
 Elekta and Royal Philips have signed agreements to deepen their existing strategic partnership to advance comprehensive and
personalized cancer care through precision oncology solutions

27. 27 Confidential
Cerner Corp.
Sample
Company Name: Cerner Corp.
Year of Establishment: 1979
Headquarter: Missouri, US
Revenue: $5.5 Bn
Website: https://www.cerner.com/
Company Profile

28. 28 Confidential
Cerner Corp.
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028

29. 29 Confidential
Varian Medical Systems, Inc.
Sample
Company Name: Varian Medical Systems, Inc.
Year of Establishment: 1948
Headquarter: California, US
Revenue: $3.2 Bn
Website: https://www.varian.com/
Company Profile

30. 30 Confidential
Varian Medical Systems, Inc.
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028

31. 31 Confidential
Qiagen N.V.
Sample
Company Name: Qiagen N.V.
Year of Establishment: 1984
Headquarter: Maryland, US
Revenue: $1.8 Mn
Website: https://www.qiagen.com/us/
Company Profile

32. 32 Confidential
Qiagen N.V.
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028

33. 33 Confidential
Becton Dickinson
Sample
Company Name: Becton Dickinson
Year of Establishment: 1897
Headquarter: New Jersey, US
Revenue: $4.8 Bn
Website: https://www.bd.com/en-us
Company Profile

34. 34 Confidential
Becton Dickinson
Breakdown of net revenue (%) by segment, 2020
Sample
Revenues ($Bn), 2020-2028
Analysis

35. 35 Confidential
Koninklijke Philips N.V.
Sample
Company Name: Koninklijke Philips N.V.
Year of Establishment: 1891
Headquarter: Netherlands
Revenue: $22.3 Bn
Website: https://www.philips.com/
Company Profile

36. 36 Confidential
Koninklijke Philips N.V.
Breakdown of net revenue (%) by segment, 2020
Analysis
Sample
Revenues ($Bn), 2020-2028

37. Healthcare Policy and Regulatory Landscape

38. 38 Confidential
Policy Changes and Regulatory Landscape
 European countries have launched specific schemes such as the UK's Early Access to Medicines Schemes (EAMS) and the
German "Heilversuch" that provide exceptional market authorization. These schemes support the notion of medicines that
address an unmet need or provide significant benefit
 Early in 2020 a law was passed in Germany which reaffirmed the ability of Gemeinsame Bundesausschuss (G-BA), the Federal
Joint Committee, to require the collection of Real World Evidence (RWE) from launch for Advanced Therapy Medicinal Products
(ATMPs). The G-BA assesses all new medicines and determines their added benefit
Sample

39. Access and Reimbursement Scenario

40. 40 Confidential
Access and Reimbursement scenario
 There is a lack of alignment between the reimbursement processes
used for medicines and companion diagnostics
 Essentially, the payment policies currently in place for complex
diagnostic/companion tests and Precision Oncology medicines are
generally considered inadequate. The bodies completing the Health
Technology Assessment process still consider large randomized
controlled trials to be the gold standard but these may be difficult to
perform for Precision Oncology medicines
Key Market Access Considerations General reimbursement Scenario
 European Commission can require the European Medicines Agencies
to conduct infringement procedures under the framework of
Commission Regulation (EC), No 658/2007, the Penalties Regulation,
into companies suspected of failing to comply with pharmacovigilance
obligations

41. Future Development Growth

42. 42 Confidential
Recent Developments in Germany Oncology Market
 In Aug 2021, Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered
biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with
precision therapeutics. Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial
focus on targets relevant to oncology and immunology
 In Aug 2021, T-knife, a Berlin-based startup, has raised 110 million U.S. dollars from international investors. The Berlin-based
biotech company is developing novel immunotherapies against cancer that focus on teaching a patient’s T cells to recognize and
fight solid tumors
 In July 2021, Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-powered cancer diagnostics and Sana Kliniken
Berlin-Brandenburg, part of Sana Kliniken AG - the third largest private hospital group in Germany, today announced the first
deployment and clinical evaluation in Germany of an AI platform that supports pathologists during routine cancer diagnosis
 In April 2021, Varian has been acquired by Siemens Healthineers. Both the companies will combinedly work towards
accelerating the path from diagnosis to therapy in cancer care

43. 43 Confidential
Future Opportunities
With the application of Artificial Intelligence in diagnosis of cancer, tumors can be detected in an early stage and the decision makers can take better
clinical decisions
Germans have seen the potential for savings from the use of biosimilars. There have been ongoing discussions to implement the use of biosimilars in
the regulation policies and encourage the prescribers to opt for biosimilars in future
Radiology and remote diagnosis portable devices can be enhanced using Artificial Intelligence enabled softwares for accurate and more informed
results
Content
Content
Content

44. Conclusion

45. 45 Confidential
Conclusion
1
2
3
5
4
Strong Demand
With the increase in number of
cancer cases with rise in ageing
population and improved
treatment options using
Immunotherapies there is a strong
growth in the oncology market
Emerging Initiative
Ease in regulations by the
government and collaborations of
companies with startups are also
building up better treatment
options for patients at lower costs
Growing Technology
Advancements
With the application of AI and
other new technology in cancer
diagnosis, treatment options can
get better and companies can
leverage on these technologies
Investment opportunity for
companies
Companies are investing in biotech
startup for the discovery of new
gene therapy or other
immunotherapy options
Government initiatives
Government policies are also
supporting companies to provide ease
of accessibility of treatment options at
lower costs to the patients